H.U. Group Holdings Inc. and its subsidiary Fujirebio have announced the launch of the Lumipulse G sTREM2 assay, a ...

The Malvern location of Fujirebio Diagnostics Inc.’s played key role in the clinical development of the first FDA-approved ...

Fujirebio collaborates with Stanford Medicine to advance research and innovation in the field of infectious disease testing: Tokyo, Japan Saturday, June 7, 2025, 13:00 Hrs [IST] F ...

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the ...

Malvern biotechnology company Fujirebio Diagnostics has developed a revolutionary new test to diagnose Alzheimer’s disease, ...

Fujirebio, a leading innovator in in-vitro diagnostics, today announced a collaboration with Stanford Medicine (Location: Palo Alto, California, USA) to advance research and innovation in the ...

The U.S. Food and Drug Administration has approved the marketing of a new tool to that can test a person’s blood to diagnose ...

The approval comes as two Alzheimer's drugs—lecanemab and donanemab—are already authorized by the FDA. Both are antibody therapies that target amyloid plaques and are believed to be more effective ...

The Food and Drug Administration (FDA) cleared the first blood test recently to help diagnose Alzheimer's disease.

The partners will work together to explore the use of a technology from Fujirebio subsidiary Fluxus in infectious disease.

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary ...